3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
18
Myelodysplastic Syndromes
10
Leukemia, Myelomonocytic, Acute
7
Leukemia, Monocytic, Acute
7
Leukemia, Promyelocytic, Acute
6
Leukemia, Megakaryoblastic, Acute
6
Leukemia, Erythroblastic, Acute
6
Congenital Abnormalities
5
Anemia, Refractory, with Excess of Blasts
4
Recurrence
3
Leukemia, Myelomonocytic, Chronic
3
Myeloproliferative Disorders
2
Sarcoma, Myeloid
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Disease Progression
1
Disease
1
Blast Crisis
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
Gemtuzumab
×
Clear all
NCT05904106
2024-12-02
VINCENT
Technische Universität Dresden
Phase 2
Recruiting
146 enrolled